I'm a provider
You will be redirected to myBlue. Would you like to continue?
Please wait while you are redirected.
Please enter a username and password.
Microwave ablation (MWA) is a technique to destroy tumors and soft tissue by using microwave energy to create thermal coagulation and localized tissue necrosis. MWA is used to treat tumors not amenable to resection or to treat patients ineligible for surgery due to age, presence of comorbidities, or poor general health. MWA may be performed as an open procedure, laparoscopically, percutaneously or thoracoscopically under image guidance (e.g., ultrasound, computed tomography, or magnetic resonance imaging) with sedation, or local or general anesthesia. This technique is also be referred to as microwave coagulation therapy.
Microwave ablation (MWA) is a technique that uses microwave energy to induce an ultra-high speed, 915 MHz or 2.450 MHz (2.45 GHz), alternating electric field, which causes water molecule rotation and creates heat. This results in thermal coagulation and localized tissue necrosis. In MWA, a single microwave antenna or multiple antennas connected to a generator are inserted directly into the tumor or tissue to be ablated; energy from the antennas generates friction and heat. The local heat coagulates the tissue adjacent to the probe, resulting in a small, approximately 2- to 3-cm elliptical area (5 x 3 cm) of tissue ablation. In tumors greater than 2 cm in diameter, 2 to 3 antennas may be used simultaneously to increase the targeted area of MWA and shorten operative time. Multiple antennas may also be used simultaneously to ablate multiple tumors. Tissue ablation occurs quickly, within 1 minute after a pulse of energy, and multiple pulses may be delivered within a treatment session, depending on tumor size. The cells killed by MWA are typically not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the margins. Treatment may be repeated as needed. MWA may be used to: 1) control local tumor growth and prevent recurrence; 2) palliate symptoms; and 3) extend survival duration.
MWA is similar to radiofrequency (RFA) and cryosurgical ablation. However, MWA has potential advantages over radiofrequency and cryosurgical ablation. In MWA, the heating process is active, which produces higher temperatures than the passive heating of radiofrequency ablation and should allow for more complete thermal ablation in less time. The higher temperatures reached with MWA (over 100°C) can overcome the “heat sink” effect in which tissue cooling occurs from nearby blood flow in large vessels potentially resulting in incomplete tumor ablation. MWA does not rely on the conduction of electricity for heating, and therefore, does not flow electrical current through patients and does not require grounding pads because there is no risk of skin burns. Additionally, MWA does not produce electric noise, which allows ultrasound guidance to occur during the procedure without interference, unlike radiofrequency ablation. Finally, MWA can take less time than radiofrequency ablation because multiple antennas can be used simultaneously.
Complications from MWA are usually considered mild and may include pain and fever. Other complications associated with MWA include those caused by heat damage to normal tissue adjacent to the tumor (e.g., intestinal damage during MWA of the kidney or liver), structural damage along the probe track (e.g., pneumothorax as a consequence of procedures on the lung), liver enzyme elevation, liver abscess, ascites, pleural effusion, diaphragm injury or secondary tumors if cells seed during probe removal. MWA should be avoided in pregnant women because potential risks to the patient and/or fetus have not been established and in patients with implanted electronic devices (eg, implantable pacemakers) that may be adversely affected by microwave power output.
MWA was first used percutaneously in 1986 as an adjunct to liver biopsy. Since then, MWA has been used to ablate tumors and tissue to treat many conditions including: hepatocellular carcinoma, breast cancer, colorectal cancer metastatic to the liver, renal cell carcinoma, renal hamartoma, adrenal malignant carcinoma, non-small-cell lung cancer, intrahepatic primary cholangiocarcinoma, secondary splenomegaly and hypersplenism, abdominal tumors, and other tumors not amenable to resection. Well-established local or systemic treatment alternatives are available for each of these malignancies. The potential advantages of MWA for these cancers include improved local control and those common to any minimally invasive procedure (e.g., preserving normal organ tissue, decreasing morbidity, shortening length of hospitalization). MWA also has been investigated as a treatment for unresectable hepatic tumors, both as primary treatment, palliative treatment, and as a bridge to liver transplant. In the latter setting, MWA is being assessed to determine whether it can reduce the incidence of tumor progression while awaiting transplantation and thus maintain a patient’s candidacy while awaiting liver transplant.
Hepatic Tumors. Hepatic tumors can arise either as primary liver cancer (hepatocellular cancer) or by metastasis to the liver from other primary cancer sites. Local therapy for hepatic metastasis may be indicated when there is no extrahepatic disease, which rarely occurs for patients with primary cancers other than colorectal carcinoma or certain neuroendocrine malignancies. At present, surgical resection with adequate margins or liver transplantation constitutes the only treatments available with demonstrated curative potential. Partial liver resection, hepatectomy, is considered the criterion standard. However, the majority of hepatic tumors are unresectable at diagnosis, due either to their anatomic location, size, number of lesions, or underlying liver reserve.
Various locoregional therapies for unresectable liver tumors have been investigated including: microwave coagulation, radiofrequency ablation, cryosurgical ablation (cryosurgery), laser ablation, trans-hepatic artery embolization/chemoembolization (TACE), percutaneous ethanol injection, and radioembolization (Yttrium-90 microspheres).
Renal Cell Carcinoma. Radical nephrectomy remains the principal treatment of renal cell carcinoma; however, partial nephrectomy or nephron-sparing surgery has been shown to be as effective as radical nephrectomy, with comparable long-term recurrence-free survival rates, in a select group of patients. Prognosis drops precipitously if the tumor extends outside the kidney capsule, since chemotherapy is relatively ineffective against metastatic renal cell carcinoma. Alternative therapies such as MWA are of interest in patients with small renal tumors when preservation of renal function is necessary (e.g., in patients with marginal renal function, a solitary kidney, bilateral tumors) and in patients with comorbidities that would render them unfit for surgery. Another consideration would be in patients at high risk of developing additional renal cancers (as in von Hippel-Lindau disease).
Several devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for MWA. Covidien’s (subsidiary of Tyco Healthcare) Evident™ Microwave Ablation System was cleared for marketing through the 510(k) process for soft tissue ablation, including partial or complete ablation of non-resectable liver tumors. The following devices have 510(k) clearance for MWA of (unspecified) soft tissue:
These devices are considered substantially equivalent to previously FDA-approved radiofrequency and MWA devices.
This policy does not address MWA for the treatment of splenomegaly or ulcers or as a surgical coagulation tool.
Related medical policies are –
POLICYMicrowave ablation of primary and metastatic tumors is considered investigational.
POLICY EXCEPTIONSFederal Employee Program (FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.
03/22/2012: Approved by Medical Policy Advisory Committee.
04/16/2013: Added the following ICD-9 procedure codes to the Code Reference section: 50.23, 50.24, 50.25, 50.29, 55.32, 55.33, 55.34, and 55.39.
01/22/2014: Policy reviewed; no changes.
12/05/2014: Policy reviewed; description updated regarding devices. Policy statement unchanged.
08/31/2015: Medical policy revised to add ICD-10 codes.
05/31/2016: Policy number added. Investigative definition updated in Policy Guidelines section.
07/07/2016: Policy description updated. Policy statement unchanged.
SOURCE(S)Blue Cross Blue Shield Association policy # 7.01.133
CODE REFERENCEThis may not be a comprehensive list of procedure codes applicable to this policy.